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The formation of new vessels from an existing vascular network in
the tumour area is essential for tumour progression and the forma-
tion of metastasis (Folkman, 1995). Therefore inhibition of angio-
genesis is a promising cancer treatment that is directed against the
delivery of nutrients, growth factors and oxygen supply to the
tumour. 
Of the numerous pro- and anti-angiogenic growth factors and
cytokines, vascular endothelial growth factor (VEGF) is an impor-
tant pro-angiogenic factor in pathological situations that involve
neovascularization and enhanced vascular permeability (Hanahan
and Folkman, 1996). Evidence for the importance of VEGF-
induced angiogenesis in tumour growth includes the observation
that neutralizing antibodies against VEGF or dominant negative
soluble receptors inhibit the growth of primary and metastatic
experimental tumours (Kim et al, 1993; Asano et al, 1995;
Borgestrom et al, 1996; Goldman et al, 1998; Kanai et al, 1998). 
The VEGF receptors Flt-1 (Fms-like tyrosine kinase, VEGF-
R1) and KDR (kinase insert domain-containing receptor, 
VEGF-R2) are almost exclusively located on endothelial cells
(Shibuya et al, 1990; Terman et al, 1992). Expression of these
receptors is low in normal tissues but they are upregulated
when neovascularization occurs (Brown et al, 1993a,b). Both
receptors have seven immunoglobulin-like domains in their extra-
cellular region, a single transmembrane-spanning domain, and an
intracellular split tyrosine kinase domain, and belong to the
same family of receptors as EGFR, PDGFR, c-Kit, 
c-Fms, Flt-3 and Flt-4. Flt-1 binds VEGF-A and -B (Olofsson
et al, 1996, 1998) and the related placental growth factor (Park et
al, 1994; Clauss et al, 1996), whereas KDR binds VEGF-A, -C and
-D (Joukov et al, 1997; Yamada et al, 1997). In contrast to Flt-1,
KDR is strongly autophosphorylated upon VEGF stimulation and
mediates the mitogenic response (Takahashi and Shibuya, 1997;
Kroll and Waltenberger, 1997). Therefore, targeting the tyrosine
kinase of the KDR VEGF receptor by small pharmacological
inhibitors represents a promising anti-angiogenic strategy for
treatment of solid tumour malignancies (Fong et al, 1999; Wood
et al, 2000). 
Whereas anti-angiogenic strategies are aimed in the first line
against the endothelial vascular system, treatment of tumours with
ionizing radiation (IR) directly targets tumour tissue. Interestingly,
recent results with combined treatment using angiostatin, a prote-
olytic fragment of plasminogen (Mauceri et al, 1998; Gorski et al,
1998) and neutralizing anti-human VEGF165 antibodies (Gorski
et al, 1999), as anti-angiogenic factors, in combination with IR
demonstrated a potentiated cytotoxic effect against endothelial
cells and an increased anti-tumoural effect of the combination
therapy in vivo. Phase I studies with angiostatin in combination
with IR are currently in progress. Likewise combined treatment
with anti-VEGFR2 monoclonal antibodies or the anti-angiogenic
compound TNP-470 significantly enhanced the growth-retarding
effect of irradiation (Teicher et al, 1996; Lund et al, 2000; Kozin
et al, 2001). 
In this report we tested the effect of combined treatment of IR in
combination with the novel, orally bioavailable VEGF receptor
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tyrosine kinase inhibitor PTK787/ZK222584 on endothelial cell
proliferation in vitro and demonstrate potent growth inhibition of
human SW480 adenocarcinoma tumour xenografts in an in vivo
mouse model by combination therapy. PTK787/ZK222584 is an
aminophthalazine derivative and is currently under clinical inves-
tigation (Wood et al, 2000; Drevs et al, 2000). 
MATERIALS AND METHODS 
Materials 
PTK787/ZK222584 (1-[4-Chloroanilino]-4-[4-pyridylmethyl]-
phthalazine succinate) was obtained from Novartis Pharma,
Switzerland. For in vitro assays, a stock solution of 10 mM of
PTK787/ZK222584 was prepared in DMSO and further diluted
in serum-containing media. Human VEGF165 was obtained from
R&D Systems. The final concentration of VEGF in all experi-
ments was 10 ng/ml. 
Cell cultures and irradiation 
Human umbilical vein endothelial cells (HUVEC, PromoCell)
were used between the fourth and the eighth passage number and
cultured for optimal cell growth conditions at 37˚C and 5% CO2
atmosphere in complete endothelial cell growth medium (EGM,
PromoCell GmbH) containing 0.4% ECGS/H, 0.1 ng/ml EGF,
1 µ g/ml hydrocortisone, 1 ng/ml bFGF, 5% fetal calf serum,
50 ng/ml amphotericin B and penicillin/streptomycin. For growth
factor starvation, cells were incubated in basal endothelial cell
media (PromoCell GmbH) supplemented with 1.5% fetal calf
serum (EBM) to minimize cell proliferation but still guarantee cell
survival. VEGF-triggered cell proliferation was induced by addi-
tion of VEGF (10 ng/ml or otherwise indicated) to EBM, i.e. in the
presence of 1.5% fetal calf serum. Before use, all tissue culture
dishes and 96-well plates were coated with 1.5% gelatin and
washed with PBS buffer, except where otherwise noted. SW480
colon adenocarcinoma cells were cultured in RPMI-1640 media
(Gibco BRL) supplemented with 10% fetal calf serum and peni-
cillin/streptomycin. Irradiation of cell cultures was carried out at
RT in tissue culture dishes (100 × 100 mm) or in 96-well plates
using a Pantak Therapax 300 kV X-ray unit at 0.7 Gy/min.
Dosimetry was controlled with a Vigilant dosimeter. 
Cell proliferation and BrdU-incorporation assay 
Human umbilical vein endothelial cells (HUVECs) (1 × 103
cells/well) were seeded in 96-well plates in EBM and allowed to
attach overnight. Pre-incubation with PTK787/ZK222584 was
performed for 2 h prior to h-VEGF165 (10 ng/ml) stimulation and
followed by irradiation 2 h later. Proliferation was assessed at
the indicated timepoints with the colorimetric AlamarBlue assay
that is based on detection of metabolite activity according to the
protocol of the manufacturer (Biosource International). Absorp-
tion was measured at 570 nm and 600 nm using a Dynatech
MR5000 spectrophotometer. Proliferation experiments with
SW480 cells were performed with 2 × 103 cells/well in RPMI-
1640 media supplemented with 1.5% FCS. BrdU (5-Bromo-2′ -
deoxy-uridine)-incorporation was performed with a BrdU-ELISA-
kit (5-Bromo-2′ -deoxy-uridine Labeling and Detection Kit III;
Boeringer Mannheim). HUVECs (1 × 103 cell/well) were plated in
EBM and treated as described for the proliferation assay (see
earlier). Cells were incubated for 24 h followed by addition of
BrdU labelling solution and a 2nd incubation was carried out
over 24 h prior to fixation, blocking and addition of peroxidase-
labelled anti-BrdU antibody. Bound antibody was detected using
a colorimetric substrate and spectrophotometrically quantified
at 405 nm and 490 nm using a Dynatech MR5000 spectropho-
tometer. Experiments were performed in triplicate and repeated at
least three times. 
Antibodies and Western blots 
HUVECs were detached from the petri dish using trypsin/EDTA,
washed in PBS, and cell pellets were immediately frozen at 
– 70˚C. The protein concentration of whole-cell lysates was deter-
mined with the BioRad DC-protein assay. Cellular proteins
(50–100 µ g) were resolved by SDS-polyacrylamide gel elec-
trophoresis and blotted onto PVDF membranes. Rabbit polyclonal
anti-cleaved caspase-3 antibody was obtained from New England
Biolabs. Antibody detection was achieved by ECL-enhanced
chemiluminescence (Amersham) using a horseradish peroxidase-
conjugated 2nd antibody, according to the manufacturer’s
protocol. 
Tumour xenografts in nude mice and administration of
chemotherapy and irradiation 
Human colon carcinoma cells (SW480) were injected subcuta-
neously (4 × 106 cells) into the flank of 4–8-week-old athymic nude
mice. Tumour volumes were determined from caliper measurements
of tumour length (L) and width (l) according to the formula (L ×
l2)/2. Tumours were allowed to expand to a volume of at least 0.175
cm3 (+/– 10%) before treatment. Using a customized shielding
device, mice were given a strictly locoregional radiotherapy of
4  × 3 Gy using a Pantak Therapax 300 kV X-ray unit at
0.7 Gy/min. PTK787/ZK222584 (dissolved in 5% DMSO, 1%
Tween-80 and 94% H2O) was applied p.o. 0.5 h prior to irradiation
at the indicated dosage. Statistical analysis was performed with the
Mann–Whitney U-test. The absolute tumour growth delay (AGD)
was defined as the time for tumour volume in the treated groups
to triplicate the initial treatment size minus the time in the untreated
control group to reach the same size (Sun et al, 1998). All animal
experiments were performed according to the ethical standards
required by the UKCCCR Guidelines (UKCCCR, 1998). 
Histological analysis 
The resected tumours were fixed in 4% buffered formalin and
embedded in paraffin for morphological analysis. Tumour sample
sections of 4–8 µ m embedded in paraffin were dewaxed with
xylene, rehydrated with hematoxylin and eosin (H&E) and the
endothelial cell-specific anti-CD31 antibody M083 (PECAM-1,
Dako) to evaluate tissue structure, quantity, morphology and size
of blood vessels. 
RESULTS 
Antiproliferative effect of PTK787/ZK222584 and IR in
endothelial cells 
The antiproliferative effect of the novel orally active VEGF
receptor tyrosine kinase inhibitor PTK787/ZK222584 alone and in2012 C Hess et al 
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combination with IR was tested with primary human umbilical
vein endothelial cells (HUVECs). Assessment of BrdU incor-
poration was used to test a short-term functional effect on cell
proliferation after treatment with increasing concentrations of
PTK787/ZK222584 (10–500 nM) alone and in combination with IR
(5, 10 Gy) using basal medium (EBM) and VEGF- supplemented
medium. HUVECs growing in EBM have a minimal proliferation
rate but the presence of 1.5% fetal calf serum still guarantees cell
survival (see Materials and methods). Cells were incubated
following treatment for 48 h and BrdU incorporation was deter-
mined during the final 24 h of the incubation period (Figure 1, A
and B). 
The basal level of HUVEC proliferation in minimal EBM
conditions supplemented with 1.5% FCS but in absence of VEGF
corresponded to 20% of the BrdU incorporation observed in
VEGF-stimulated cells. Increasing concentrations of PTK787/
ZK222584 did not affect the basal level of BrdU incorporation in
the absence of VEGF, but induced a dose-dependent decrease of
proliferation in HUVECs when stimulated with VEGF. BrdU
incorporation was reduced to basal levels when cells were treated
with PTK787/ZK222584 concentrations above 100 nM. These
results demonstrate the specific anti-VEGF-receptor-directed
growth inhibitory effect of PTK787/ZK222584 (Figure 1B).
Irradiation of HUVECs with 5 Gy or 10 Gy in the absence of
VEGF even abrogated the basal proliferative activity, indicative of
a complete IR-induced arrest of cell proliferation. When cells were
grown in the presence of VEGF, irradiation with 5 Gy and 10 Gy
decreased the amount of BrdU incorporation to 42% and 10%,
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Figure 1 Treatment with PTK787/ZK222584 alone and in combination with IR decreases the VEGF-dependent proliferative activity of HUVECs. HUVECs
were treated with increasing doses of PTK787/ZK222584 and IR alone and in combination, in the absence (A) or presence of VEGF (B). BrdU-incorporation
was determined 24 h after treatment during an additional 24-hour incubation period. The negative values are due to unspecific but enhanced BrdU/anti-BrdU
antibody detection in control samples without cells. The prolonged antiproliferative effect on HUVECs in the presence of VEGF after treatment with increasing
doses of PTK787/ZK222584 alone (C) and in combination with IR (D) was determined 48 h and 96 h with the MTT-like alamarblue assay. The proliferative
activity of the cells prior to treatment was determined and set as 100%. Data show the mean of one representative experiment ± SDPTK787/ZK222584 and ionizing radiation  2013
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respectively. Combined treatment with PTK787/ZK222584 and
irradiation showed an additive antiproliferative effect on VEGF-
stimulated BrdU incorporation at low PTK787/ZK222584 concen-
trations (10, 50 nM). 
The proliferative activity of HUVECs upon treatment with
increasing concentrations of PTK787/ZK222584 and IR alone and
in combination, was also determined at later timepoints (48 h and
96 h) using the MTT-like colorimetric alamarBlue assay that is
based on detection of metabolic activity. Similar to the short-term
proliferation assay, the dose-dependent effect of PTK787/
ZK222584 on HUVEC proliferation was still observed at later
timepoints (Figure 1C). Likewise irradiation (10 Gy) alone
resulted in a decreased metabolic activity that corresponded with
66% of untreated cells at the 48 h and 96 h timepoints. Combined
treatment with PTK787/ZK222584 and IR resulted in an additive
reduction of proliferative activity determined at these timepoints
(Figure 1D). 
No apoptosis induction by combined treatment 
HUVECs undergo apoptosis after loss of adhesion or serum
deprivation. The reduced proliferative activity observed in the
HUVEC population upon treatment with PTK787/ZK222584
alone or in combination with IR might be due to the induction of
apoptosis. However no morphological signs of apoptosis were
observed during the course of treatment (data not shown). In
order to detect any biochemical parameters of apoptosis induc-
tion, processing of the major effector caspase-3 was detected in
cellular extracts by Western blotting with anti-cleaved caspase-3
antibody. This antibody only recognizes the active form of
caspase-3. Treatment of cells that were incubated in the presence
of VEGF-containing EBM media supplemented with 1.5% fetal
calf serum, with PTK787/ZK222584 (100 nM), IR (10 Gy) or
in combination did not induce any processing of caspase-3 to
its active form, while cultivation of cells in EBM media in
the absence of 1.5% serum and VEGF resulted in caspase-3
processing (Figure 2A). 
The cellular response of HUVECs depends highly on the
experimental conditions, e.g. absence or minimal serum present
during treatment. Likewise no apoptosis induction was observed
in the presence of minimal serum (1.5%) and VEGF
upon combined treatment with IR and PTK787/ZK222584, at
concentrations that induced apoptosis by treatment with
PTK787/ZK222584 alone but in absence of serum (Wood et al,
2000). 
Control experiments were performed with HUVECs cultivated
in the presence of increased serum levels (10%). PTK787/
ZK222584 did not decrease the highly proliferative activity
observed under these conditions, which is most probably due to
the high abundance of growth stimulatory factors in serum (data
not shown). 
Treatment of SW480 tumour xenografts with IR and
PTK787/ZK222584 
The low molecular weight synthetic inhibitor PTK787/ZK222584
is active after oral administration and is currently undergoing 
clinical trial in cancer patients. Based on the additive in vitro
effects, combined treatment with PTK787/ZK222584 and frac-
tionated irradiation was tested in vivo against tumour xenografts
derived from the p53-mutated, human colon adenocarcinoma cell
line SW480. To exclude a direct effect of PTK787/ZK222584 on
the SW480 tumour cells, control experiments were performed to
test the anti-proliferative effect of PTK787/ZK222584 on this
cell line. Treatment with increasing concentration of PTK787/
ZK222584 had no effect on the proliferation of these cells consis-
tent with the absence of KDR receptor expression in this cell line.
Combined treatment with PTK787/ZK222584 and irradiation in
vitro did not result in any additional inhibitory effect of
PTK787/ZK222584 over the response induced by irradiation alone
(Figure 2B). 
Tumour xenografts were obtained upon subcutaneous injection of
SW480 cells (4 × 106) into the flank of nude mice and treatment was
started when tumours reached a minimal size of 175 mm3 ± 10%
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Figure 2 PTK787/ZK222584 does not induce apoptosis in HUVECs and has no antiproliferative effect on SW480 cells. (A) HUVECs in EBM (1.5% FCS) and
EBM supplemented with VEGF (10 ng/ml) were treated with PTK787/ZK222584 (100 nM), IR (10 Gy) and in combination. Cells were harvested 48 h after
treatment and analysed for caspase-3 processing. The first lane is a control sample taken at the 0 h timepoint of cultivation in the specified media. Equal
protein loading was verified with an anti-β -actin monoclonal antibody. Cell lysate from HUVECs cultivated in the absence of serum and VEGF was 
co-loaded as an apoptotic control sample. (B) Proliferation of SW480 cells, in RPMI-1640, 1.5% FCS and VEGF (10 ng/ml), was assessed 96 h after treatment
with increasing doses of PTK787/ZK222584 alone and in combination with IR. The proliferative activity of the cells prior to treatment was determined and 
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(days 12–17 after cell injection). Figure 3 summarizes the effect of
treatment against SW480-derived tumours with PTK787/ZK222584
alone (4 × 100 mg/kg), IR alone (4 × 3 Gy), and in combination (4 ×
100 mg/kg combined with 4 × 3 Gy) applied on 4 consecutive days,
in comparison with an untreated control group. Each curve repre-
sents the mean tumour volume per group (n = quantity of animals
per group). A daily dose of 3 Gy was chosen as a clinically relevant
fraction size for the treatment of human malignancies. For practical
reasons, only four fractions were chosen as a treatment regimen, but
the response to such a regimen is useful for evaluation of radiosensi-
tization and treatment. Treatment with PTK787/ZK222584 or IR
alone resulted in minimal growth delay, whereas combined treat-
ment exerted a strong tumour growth control during treatment and
the follow-up period. In this human colon tumour xenograft, a
significant AGD to triplicate the tumour volume was observed upon
combined treatment in comparison to the AGD upon treatment with
IR or PTK787/ZK222584 alone (21 days vs 2 or 1 days, respec-
tively) resulting in prolonged tumour growth control (P = 0.003, RT
vs combined treatment). Examination of the tumours during and
after the different treatments revealed that tumour tissue appeared to
be much less vascularized (white-shining) after combined treatment
in comparison to untreated tumours or after either treatment
modality alone (data not shown). 
Histological analysis of microvessel density 
Histopathological examination of control SW480 tumours revealed
a dense network of distended microvessels localized in the central
part of the tumour (Figure 4). Moreover a large number of vital
microvessels were located at the border and focally in the
necrotic and apoptotic tumour areas. In contrast, SW480 tumours
with the combined therapy displayed a dramatically decreased
number of microvessels, often with only a very thin diameter
located almost exclusively in the vital parts of the tumours. SW480
tumours treated either with PTK787/ZK222584 or IR alone showed
comparable microvessel density to the control group. Tumours of
all treatment groups revealed extensive necrosis and apoptosis,
usually only with a thin wall of vital tumour at the periphery.
Owing to a dramatically decreased tumour volume after combined
treatment, the total area of necrotic and apoptotic zones appears
relatively enlarged in comparison to control tumours. 
DISCUSSION 
Radiotherapy is an important treatment modality for many solid
human cancers but often unsuccessful because of an intrinsic or
acquired radiation resistance of the tumour. Solid tumours require
angiogenesis for growth, and inhibition of angiogenesis is one
promising strategy for cancer therapy. Therefore a combined treat-
ment approach using pharmacological inhibitors of angiogenesis
and ionizing radiation has a sound rationale for both targets within
a solid tumour and the potential lack of supra-additive toxicity. 
Here we have demonstrated the combined treatment modality
of irradiation with PTK787/ZK222584, a specific low molecular
inhibitor of the VEGF receptor tyrosine kinase that is currently
under clinical investigation for its anti-angiogenic activity and is
active upon oral application. In vitro, combined treatment with
PTK787/ZK222584 and irradiation against human umbilical vein
endothelial cells resulted in an additive antiproliferative effect. In
comparison to other reports, we could not detect a supra-additive
cytotoxic in vitro effect on endothelial cell proliferation as
observed upon treatment with irradiation in combination with an
angiogenic inhibitor in clonogenic assays (Mauceri et al, 1998;
Gorski et al, 1999). Furthermore no apoptosis induction was
observed in our experimental set-up. Our results indicate that the
antiproliferative effect induced with PTK787/ZK222584 or IR as
single agents or the combination of both might be due to a tran-
sient cell cycle arrest as detected by the abrogated BrdU incorpo-
ration at the early timepoints and a subsequent lower level of
proliferative activity in the cell population at the later timepoints. 
In vivo, combined treatment with four daily fractions of low-
dose ionizing irradiation induced a strong cooperative growth
control effect at doses of IR and PTK787/ZK222584 that had
almost no effect when used as a single agent alone. These results
are consistent with earlier observations that VEGF-dependent
growth is a key factor for in vivo tumour neovascularization and
a potential target for combined treatment modalities (Shibuya,
1995; Takahashi et al, 1995; Mauceri et al, 1998; Gorski et al,
1999; Kozin et al, 2001). With a treatment regimen of four frac-
tions of IR applied on four consecutive days in vivo, we found
both a significant suppra-additive, antitumoral effect and a lack
of additive toxicity, indicating a potentially broad therapeutic
window. We did not observe any immediate or long-term unspe-
cific toxicities during treatment and the follow-up period.
The results obtained with low doses of both irradation and
PTK787/ZK222584 are encouraging with regard to the translation
of the findings into potential phase I studies for cancer patients.
Thus, it would be interesting to test an extended combined treat-
ment regimen against these tumour xenografts, in particular
since the daily dose and number of fractions of IR and dose of
PTK787/ZK222584 is well below the maximal daily tolerated
dose of IR or PTK787/ZK222584 that could be given over an
extended period of time (Wood et al, 2000). 
Recently, inhibition of the VEGF receptor by the Flk-1 kinase
inhibitor SU5416 was demonstrated to revert radiation resistance
of refractory tumour blood vessels and enhanced the cytotoxic
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effects of radiotherapy (Geng et al, 2001). Our results support the
antitumoral therapeutic strategy of combining small, specific
inhibitors of intracellular protein kinases with irradiation (Zaugg
et al, 2001). In contrast to SU5416, PTK787/ZK222584 is active
after oral administration and displays an increased specificity
towards VEGF receptor tyrosine kinases compared to SU5416
(Fong et al, 1999; Wood et al, 2000). 
Treatment with PTK787/ZK222584 and irradiation might coop-
erate on various levels with regard to tumour control. Irradiation
targets both tumour and endothelial cells and as part of a stress
response also enhances the expression of VEGF in the tumour
tissue (Gorski et al, 1999). PTK787/ZK222584 downregulates the
VEGF-dependent proliferative activity of the tumour microvascu-
lature and concomitantly blocks the enhanced VEGF-mediated
survival processes in response to irradiation (Gorski et al, 1999;
Geng et al, 2001). Thus the molecular analysis of VEGF-
dependent survival pathways in endothelial cells and the interac-
tion with the irradiated tumour tissue will be of great importance
to advance this rapidly developing concept of a cooperative
tumour growth control effect by angiogenesis inhibitors in combi-
nation with irradiation. 
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